EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The impact of diabetes on cancer detection during the prevalence round of a national screening program for colorectal cancer

Susanne Boel Graversen, Anne Østergaard Nannsen, Lasse Bjerg, Mette Bach Larsen, Berit Andersen, Tinne Laurberg iD

Diabetic Medicine · 2023

DOI: 10.1111/dme.15043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetic Medicine, 2023. Verfasst von Susanne Boel Graversen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus N, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Colorectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Danish Diabetes Academy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Diabetes is associated with a higher risk of colorectal cancer (CRC) and inferior survival after CRC. Screening may enable the early detection of CRC. We aimed to assess the impact of diabetes on cancer detection and disease stage during the prevalence round of a national CRC screening program.

Methods

We performed a register‐based cohort study based on the randomized procedure for inviting Danish residents aged 50–74 years to the prevalence round of national CRC screening program in 2014–2017. By comparing the random half of the population who had been invited by 1 May 2016 with the not yet invited half, the effect of screening was assessed by the detection of CRC and disease stage among individuals with and without diabetes. Further, the impact of diabetes on the screening participation rate was calculated.

Results

By randomisation, 504,673 individuals had been invited to the CRC screening by 1 May 2016, and 549,359 individuals had not yet been invited. The diabetes prevalence was 10% in both groups. When comparing those not yet invited to those invited, the effect of screening on the number of detected cancers per 100,000 individuals was higher in those with diabetes (from 207 to 494 cancers) than in those without diabetes (from 147 to 364 cancers), and screening resulted in overall higher proportions of stage I cancer. Among those invited to screening, the participation rate was 9.1% lower (95% CI: 8.7%–9.5%) in individuals with versus without diabetes.

Conclusions

Despite a lower participation rate, the effect of CRC screening was higher in individuals with diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes MellitusColorectal NeoplasmsHumansCohort StudiesPrevalenceEarly Detection of CancerOccult BloodMass Screening

Stichwörter der Autor:innen

cohort studiescolorectal neoplasmsdiabetes mellitusmass screening

Autor:innen und Institutionen

  • Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus N, Denmark.
  • Department of Public Health, Aarhus University, Aarhus C, Denmark.
  • Department of Public Health Programmes, University Research Clinic for Cancer Screening, Randers Regional Hospital, Randers NØ, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.

ORCID-Profile: Tinne Laurberg

Förderung

  • Danish Diabetes Academy

Zitieren

APA

Graversen, S. B., Nannsen, A. Ø., Bjerg, L., Larsen, M. B., Andersen, B., & Laurberg, T. (2023). The impact of diabetes on cancer detection during the prevalence round of a national screening program for colorectal cancer. Diabetic Medicine. https://doi.org/10.1111/dme.15043

Vancouver

Graversen SB, Nannsen AØ, Bjerg L, Larsen MB, Andersen B, Laurberg T. The impact of diabetes on cancer detection during the prevalence round of a national screening program for colorectal cancer. Diabetic Medicine. 2023. doi:10.1111/dme.15043

BibTeX
@article{Graversen2023,
  author = {Graversen, Susanne Boel and Nannsen, Anne Østergaard and Bjerg, Lasse and Larsen, Mette Bach and Andersen, Berit and Laurberg, Tinne},
  title = {The impact of diabetes on cancer detection during the prevalence round of a national screening program for colorectal cancer},
  journal = {Diabetic Medicine},
  year = {2023},
  doi = {10.1111/dme.15043}
}
Kostenlos starten →